Nicox S.A. Overview
Nicox S.A., a health care biotechnology company based in Valbonne, France, is dedicated to researching, developing, and marketing therapies for various ophthalmic conditions. Founded in 1996, Nicox has established itself as a key player in the biotechnology sector, focusing on innovative treatments for eye diseases.
Product Pipeline and Collaborations
The company’s product pipeline includes several promising candidates:
- Vyzulta™: An intraocular pressure-lowering treatment.
- NCX 470: A nitric oxide (NO)-donating candidate aimed at treating glaucoma.
- Stand-alone NO donors: Designed for specific applications in ophthalmic diseases.
- ZERVIATE: An eye drop formulation of cetirizine for allergic conjunctivitis.
- NCX 4280: An ophthalmic solution targeting morning ocular congestion.
- NCX 4251: A patented formulation of fluticasone propionate to treat blepharitis.
Nicox has established collaborations with several major pharmaceutical companies, including Bausch + Lomb, AstraZeneca, Merck, Pfizer, and Ironwood Pharmaceuticals, Inc., as well as Novaliq GmbH. These partnerships are crucial for advancing its research and development efforts.
Financial Overview
As of July 15, 2025, Nicox’s close price was 0.226 EUR. The company’s market capitalization stands at 16,350,000 EUR. Over the past year, the stock has experienced significant fluctuations, reaching a 52-week high of 0.335 EUR on January 2, 2025, and a low of 0.14 EUR on September 12, 2024. The price-to-earnings ratio is currently -0.734915, reflecting the company’s financial performance and market expectations.
Market Presence
Nicox is listed on both the NYSE and Euronext Paris stock exchanges, allowing it to access a broad investor base. The company continues to focus on expanding its reach both nationally and internationally, aiming to bring its innovative ophthalmic therapies to a wider audience.
For more information, visit Nicox’s website at www.nicox.com .